118 related articles for article (PubMed ID: 32933939)
1. Adjuvant use of laser in eyes with macular retinoblastoma treated with primary intravenous chemotherapy.
Stacey AW; Tsukikawa M; Fabian ID; Turner S; Jenkinson H; Smith V; Naeem Z; Morland B; Ainsworth JR; Reddy MA; Parulekar M; Sagoo MS
Br J Ophthalmol; 2021 Nov; 105(11):1599-1603. PubMed ID: 32933939
[TBL] [Abstract][Full Text] [Related]
2. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation.
Schefler AC; Cicciarelli N; Feuer W; Toledano S; Murray TG
Ophthalmology; 2007 Jan; 114(1):162-9. PubMed ID: 17070578
[TBL] [Abstract][Full Text] [Related]
3. Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode laser a risk factor?
Gombos DS; Cauchi PA; Hungerford JL; Addison P; Coen PG; Kingston JE
Br J Ophthalmol; 2006 Sep; 90(9):1168-72. PubMed ID: 16707528
[TBL] [Abstract][Full Text] [Related]
4. Management and outcome of retinoblastoma with vitreous seeds.
Manjandavida FP; Honavar SG; Reddy VA; Khanna R
Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675
[TBL] [Abstract][Full Text] [Related]
5. Prospective phase II study of children affected by bilateral intraocular retinoblastoma with macular involvement of both eyes or in the only preserved eye. Macular tumor control, eye preservation rate, and visual outcome.
Russo I; Levy-Gabriel C; Dupont A; Lumbroso-Le Rouic L; Cassoux N; Desjardins L; Bertozzi AI; Coze C; Doz F; Savignoni A; Aerts I
Pediatr Blood Cancer; 2021 Jan; 68(1):e28721. PubMed ID: 33098751
[TBL] [Abstract][Full Text] [Related]
6. Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma.
Berry JL; Bechtold M; Shah S; Zolfaghari E; Reid M; Jubran R; Kim JW
Ophthalmology; 2017 Dec; 124(12):1817-1825. PubMed ID: 28655537
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma.
Zage PE; Reitman AJ; Seshadri R; Weinstein JL; Mets MB; Zeid JL; Greenwald MJ; Strauss LC; Goldman S
Pediatr Blood Cancer; 2008 Mar; 50(3):567-72. PubMed ID: 17729249
[TBL] [Abstract][Full Text] [Related]
8. Treatment of small and medium retinoblastoma tumors with Iris diode laser.
Reynolds MM; Sein J; Hayashi R; Lueder G
Eur J Ophthalmol; 2021 Nov; 31(6):3318-3323. PubMed ID: 33530736
[TBL] [Abstract][Full Text] [Related]
9. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma.
Shields CL; Shields JA; Needle M; de Potter P; Kheterpal S; Hamada A; Meadows AT
Ophthalmology; 1997 Dec; 104(12):2101-11. PubMed ID: 9400771
[TBL] [Abstract][Full Text] [Related]
10. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Ness S; Meadows AT; Shields JA
Arch Ophthalmol; 2005 Jun; 123(6):765-73. PubMed ID: 15955977
[TBL] [Abstract][Full Text] [Related]
11. Salvage external beam radiotherapy after failed primary chemotherapy for bilateral retinoblastoma: rate of eye and vision preservation.
Chan MP; Hungerford JL; Kingston JE; Plowman PN
Br J Ophthalmol; 2009 Jul; 93(7):891-4. PubMed ID: 19329423
[TBL] [Abstract][Full Text] [Related]
12. Visual prognosis of retinoblastoma in the posterior pole treated with primary chemotherapy plus local treatments.
Kim JM; Kim JH; Kim SJ; Park KD; Shin HY; Ahn HS; Yu YS
Korean J Ophthalmol; 2010 Dec; 24(6):347-52. PubMed ID: 21165233
[TBL] [Abstract][Full Text] [Related]
13. A 10-year experience of outcome in chemotherapy-treated hereditary retinoblastoma.
Bartuma K; Pal N; Kosek S; Holm S; All-Ericsson C
Acta Ophthalmol; 2014 Aug; 92(5):404-11. PubMed ID: 24119165
[TBL] [Abstract][Full Text] [Related]
14. Chemoreduction for unilateral retinoblastoma.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Naduvilath TJ
Arch Ophthalmol; 2002 Dec; 120(12):1653-8. PubMed ID: 12470138
[TBL] [Abstract][Full Text] [Related]
15. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma.
Shields CL; Honavar SG; Shields JA; Demirci H; Meadows AT; Naduvilath TJ
Arch Ophthalmol; 2002 Apr; 120(4):460-4. PubMed ID: 11934319
[TBL] [Abstract][Full Text] [Related]
16. Rescue intra-arterial chemotherapy following retinoblastoma recurrence after initial intra-arterial chemotherapy.
Shields CL; Say EA; Pointdujour-Lim R; Cao C; Jabbour PM; Shields JA
J Fr Ophtalmol; 2015 Jun; 38(6):542-9. PubMed ID: 25982423
[TBL] [Abstract][Full Text] [Related]
17. Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.
Künkele A; Jurklies C; Wieland R; Lohmann D; Bornfeld N; Eggert A; Schulte JH
Br J Ophthalmol; 2013 Oct; 97(10):1277-83. PubMed ID: 23863458
[TBL] [Abstract][Full Text] [Related]
18. Visual outcome in macular retinoblastoma treated with primary chemotherapy.
Balasubramanya R; Pushker N; Bajaj MS; Rani A; Ghose S; Arya LS
Ophthalmologica; 2003; 217(6):417-21. PubMed ID: 14573975
[TBL] [Abstract][Full Text] [Related]
19. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
Gündüz K; Günalp I; Yalçindağ N; Unal E; Taçyildiz N; Erden E; Geyik PO
Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
[TBL] [Abstract][Full Text] [Related]
20. Predictors of long-term visual outcome after chemoreduction for management of intraocular retinoblastoma.
Narang S; Mashayekhi A; Rudich D; Shields CL
Clin Exp Ophthalmol; 2012; 40(7):736-42. PubMed ID: 22300311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
